Drug Trial Radar · NCT07939971
A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- TuHURA Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional study is to learn if TBS-2025 is safe to administer to participants with relapsed/refractory (r/r) Acute Myeloid Leukemia (AML). The main questions it aims to answer are: * What medical problems do adult participants have when taking TBS-2025? * What does the body do from the time TBS-2025 enters the body until it is completely gone? * What is the best dose of TBS-2025 to give to participants? * Does TBS-2025 work to treat r/r AML? Participants will: * Take TBS-2025 every 2 weeks * Visit the clinic every 1 to 2 weeks for checkups and tests
Conditions
- Acute Myeloid Leukemia
Interventions
TBS-2025Biological
TBS-2025 is a fully human IgG1-kappa monoclonal antibody that binds specifically to the hVISTA-ECD and blocks interaction with endogenous VISTA ligands.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs)Time frame: At the end of Cycle 1 ( each cycle is 28 days)
- Number of participants with an AETime frame: Baseline through study completion, an average of 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.